Stock Analiz

Ultralife Corp. ULBI

Industrial Machinery/Components · IPO 1992 · data as of November 13, 2026

$15.73Market cap $262M
Open the interactive analysis →

Ultralife Corp. (ULBI) is a company listed in the US with a market value of about $262M. In the twelve months to September 30, 2026 it had revenue of $192M and net income of -$3M, a net margin of -1.5%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 12% a year, a 5-year average ROIC of 1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.

About Ultralife

Ultralife is listed in the US and classified in industrial machinery/components, IPO year 1992. Revenue went from $66M in 2014 to $191M in 2025, growth of about 10.1% a year. It was profitable in 7 of the last 10 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 5% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.4
P/B1.9
EV/EBITDA236.6
PEG—
Dividend yield0.00%
FCF yield-0.3%
Shareholder yield0.0%
Intrinsic value vs. price−60%

Growth and quality

Revenue growth (1 yr)16.2%
Revenue growth (5 yrs, per year)12.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)1.0%
ROIC (5-yr avg.)1.3%
Profitable years (of last 10)7
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$192M$191M$164M$159M$132M$98M$108M$107M$87M$86M$82M
Net income-$3M-$6M$6M$7M-$119000-$234000$5M$5M$25M$8M$4M
Free cash flow-$694000$7M$15M-$623000-$3M$2M$19M-$9M$7M$6M$6M
EPS (diluted)$-0.18$-35.00$38.00$0.44$0.05$0.05$0.00$32.00$1.53$0.00$0.23
Net margin-1.5%-3.1%3.8%4.5%-0.1%-0.2%4.9%4.9%28.6%8.9%4.3%
ROIC—-2.3%4.0%4.8%0.1%0.0%3.7%4.5%4.9%6.5%5.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Ultralife stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Ultralife pay a dividend?

Not currently.

Is Ultralife a good stock to buy?

We do not give buy or sell advice. Ultralife scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.